scholarly journals Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives

Cells ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 1164
Author(s):  
Flavia Lima Costa Faldoni ◽  
Cláudia Aparecida Rainho ◽  
Silvia Regina Rogatto
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Histone Deacetylase Inhibitors ◽  
Clinical Presentation ◽  
Lymphatic Invasion ◽  
Common Denominator ◽  
Epigenetic Alterations ◽  
Diffuse Erythema ◽  
Peau D’Orange ◽  
Mammary Gland Differentiation

Evidence has emerged implicating epigenetic alterations in inflammatory breast cancer (IBC) origin and progression. IBC is a rare and rapidly progressing disease, considered the most aggressive type of breast cancer (BC). At clinical presentation, IBC is characterized by diffuse erythema, skin ridging, dermal lymphatic invasion, and peau d’orange aspect. The widespread distribution of the tumor as emboli throughout the breast and intra- and intertumor heterogeneity is associated with its poor prognosis. In this review, we highlighted studies documenting the essential roles of epigenetic mechanisms in remodeling chromatin and modulating gene expression during mammary gland differentiation and the development of IBC. Compiling evidence has emerged implicating epigenetic changes as a common denominator linking the main risk factors (socioeconomic status, environmental exposure to endocrine disruptors, racial disparities, and obesity) with IBC development. DNA methylation changes and their impact on the diagnosis, prognosis, and treatment of IBC are also described. Recent studies are focusing on the use of histone deacetylase inhibitors as promising epigenetic drugs for treating IBC. All efforts must be undertaken to unravel the epigenetic marks that drive this disease and how this knowledge could impact strategies to reduce the risk of IBC development and progression.

scholarly journals Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next generation plasma biopsy-based diagnostic biomarkers for inflammatory breast cancer

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0250642
Author(s):  
Sarah Hamdy Ahmed ◽  
Nancy A. Espinoza-Sánchez ◽  
Ahmed El-Damen ◽  
Sarah Atef Fahim ◽  
Mohamed A. Badawy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Inflammatory Breast Cancer ◽  
Roc Curves ◽  
Cost Effective ◽  
Extracellular Vesicle ◽  
Lymphatic Invasion ◽  
Precipitation Method ◽  
Liquid Biopsies ◽  
Diagnostic Biomarkers

Inflammatory breast cancer (IBC) is a rare, but aggressive entity of breast carcinoma with rapid dermal lymphatic invasion in young females. It is either poorly or misdiagnosed as mastitis because of the absence of a distinct lump. Small extracellular vesicles (sEVs) circulating in liquid biopsies are a novel class of minimally invasive diagnostic alternative to invasive tissue biopsies. They modulate cancer progression via shuttling their encapsulated cargo including microRNAs (miRNAs) into recipient cells to either trigger signaling or induce malignant transformation of targeted cells. Plasma sEVs < 200 nm were isolated using a modified cost-effective polyethylene glycol (PEG)-based precipitation method and compared to standard methods, namely ultracentrifugation and a commercial kit, where the successful isolation was verified by different approaches. We evaluated the expression levels of selected sEV-derived miR-181b-5p, miR-222-3p and let-7a-5p using quantitative real PCR (qPCR). Relative to non-IBC, our qPCR data showed that sEV-derived miR-181b-5p and miR-222-3p were significantly upregulated, whereas let-7a-5p was downregulated in IBC patients. Interestingly, receiver operating characteristic (ROC) curves analysis revealed that diagnostic accuracy of let-7a-5p alone was the highest for IBC with an area under curve (AUC) value of 0.9188, and when combined with miR-222-3p the AUC was improved to 0.973. Further, 38 hub genes were identified using bioinformatics analysis. Together, circulating sEV-derived miR-181b-5p, miR-222-3p and let-7a-5p serve as promising non-invasive diagnostic biomarkers for IBC.

Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer

2004 ◽  
Vol 109 (1) ◽  
pp. 144-148 ◽  
Author(s):  
Guenther Gruber ◽  
Michele Ciriolo ◽  
Hans Joerg Altermatt ◽  
Stefan Aebi ◽  
Gilles Berclaz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Clinical Signs ◽  
Lymphatic Invasion

Dermal Lymphatic Invasion and Inflammatory Breast Cancer Are Independent Predictors of Outcome After Postmastectomy Radiation

2009 ◽  
Vol 32 (1) ◽  
pp. 30-33 ◽  
Author(s):  
Matthew C. Abramowitz ◽  
Tianyu Li ◽  
Monica Morrow ◽  
Elin R. Sigurdson ◽  
Penny Anderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Lymphatic Invasion ◽  
Predictors Of Outcome ◽  
Postmastectomy Radiation

Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Kelly A. Hirko ◽  
Meredith M. Regan ◽  
Marie C. Remolano ◽  
Julia Schlossman ◽  
Beth Harrison ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Lymphatic Invasion ◽  
Time To Recurrence

scholarly journals High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Anita Rogic ◽  
Ila Pant ◽  
Luca Grumolato ◽  
Ruben Fernandez-Rodriguez ◽  
Andrew Edwards ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Growth ◽  
Inflammatory Breast Cancer ◽  
Xenograft Model ◽  
Lymphatic Invasion ◽  
Therapeutic Approaches ◽  
Ccl2 Expression ◽  
Mouse Xenograft Model ◽  
Skin Erythema ◽  
Key Factor

AbstractInflammatory Breast Cancer (IBC) is a highly aggressive malignancy with distinct clinical and histopathological features whose molecular basis is unresolved. Here we describe a human IBC cell line, A3250, that recapitulates key IBC features in a mouse xenograft model, including skin erythema, diffuse tumor growth, dermal lymphatic invasion, and extensive metastases. A3250 cells express very high levels of the CCL2 chemokine and induce tumors enriched in macrophages. CCL2 knockdown leads to a striking reduction in macrophage densities, tumor proliferation, skin erythema, and metastasis. These results establish IBC-derived CCL2 as a key factor driving macrophage expansion, and indirectly tumor growth, with transcriptomic analysis demonstrating the activation of multiple inflammatory pathways. Finally, primary human IBCs exhibit macrophage infiltration and an enriched macrophage RNA signature. Thus, this human IBC model provides insight into the distinctive biology of IBC, and highlights potential therapeutic approaches to this deadly disease.

Multicenter, prospective study of radiotherapy without surgery after AC followed by weekly paclitaxel for patients with inflammatory breast cancer: SBCCSG-04 study

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10783-10783 ◽  
Author(s):  
T. Tabei ◽  
K. Sato ◽  
K. Inoue ◽  
S. Nakano ◽  
T. Kai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Inflammatory Breast Cancer ◽  
Disease Free Survival ◽  
Lymphatic Invasion ◽  
Weekly Paclitaxel ◽  
Treatment Schedule ◽  
Distant Disease ◽  
Multicenter Prospective Study ◽  
Disease Free

10783 Background: Inflammatory breast cancer (IBC) is a rare and aggressive disease with a dismal outcome. It is still an open debate whether surgery is beneficial for patients with IBC. This study was conducted to evaluate treatment results when patients were treated by chemotherapy and radiotherapy (CRT) alone. Methods: 52 pts with nonmetastatic IBC were enrolled for a prospective registration trial from 9/01–11/04. A diagnosis required the presence of erythema, ridging, or peau d’orange, with or without dermal lymphatic invasion (DLI). All patients were invited to participate for an experimental protocol; 4 cycles of AC and 12 cycles of weekly paclitaxel (80 mg/m2) followed by radiotherapy. In patients who did not agree to the protocol, the decision about treatment was left to the patients/investigators. The primary endpoint was distant-disease-free survival, and the further endpoints were locoregional relapse (LR) and overall survival. Results: The mean follow-up was 25.7 months. 24 pts (46.2%) were planned for the protocol, but one pt (4%) was receipt surgery. Otherwise, 18 (64%) out of 28 pts have accepted mastectomy. The 2-year distant-disease-free, LR, and overall survival in patients treated with and without the protocol was 35.2 vs 61.0% (HR = 2.4, 1.1–5.3) and 55.2 vs 83.6% (HR = 2.9, 1.1–7.8), respectively. Surgery was not associated with the risk of LR (p = 0.48). There was marginally worse prognosis in patients with DLI. Conclusions: There was a limitation because this comparison had not been conducted a randomized fashion. However, CRT alone would be a feasible treatment schedule for a moderate percentage of patients with IBC. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document